Role of radiolabeled octreotide therapy in patients with metastatic neuroendocrine neoplasms

Expert Review of Endocrinology and Metabolism

Volumn 2, Issue 4, 2007, Pages 517-527

  Frilling, Andrea ^a   Weber, Frank ^a   Cicinnati, Vito ^a   Broelsch, Christoph ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

DOTATOC; Metastases; Neuroendocrine tumor; Octreotide; Peptide receptor radiotherapy; Somatostatin receptor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; AMINO ACID; ANGIOPEPTIN; BEVACIZUMAB; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; GALLIUM 68; IMATINIB; LUTETIUM 177; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; OCTREOTIDE; PASIREOTIDE; PENTETATE INDIUM IN 111; PENTETIC ACID; PENTETREOTIDE; PENTETREOTIDE IN 111; PEPTIDE DERIVATIVE; RECEPTOR PROTEIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; STREPTOMYCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG; YTTRIUM 90;

ANEMIA; ARTIFICIAL EMBOLISM; BONE MARROW SUPPRESSION; CANCER LOCALIZATION; CANCER SURVIVAL; CARCINOID SYNDROME; CHOLELITHIASIS; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; ENDOCRINE SURGERY; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERGLYCEMIA; HYPERTHERMIC THERAPY; HYPOTHYROIDISM; ISOTOPE LABELING; KIDNEY FAILURE; LABORATORY TEST; LIVER METASTASIS; LYMPHOCYTOPENIA; METASTASIS POTENTIAL; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUROSURGERY; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN TARGETING; QUALITY OF LIFE; RADIOFREQUENCY RADIATION; RECOMMENDED DRUG DOSE; RENAL PROTECTION; REVIEW; SINUS TACHYCARDIA; STEATORRHEA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING;

EID: 34547532453     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/17446651.2.4.517     Document Type: Review

References (105)

1. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann. NY Acad. Sci. 1014, 13-27 (2004).
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97(4), 934-959 (2003).
3. Willams ED, Sandler M. The classification of carcinoid tumours. Lancet 1, 238-239 (1963).
4. Moertel CG, Sauer WG, Dockerty MB, Baggenstoss AH. Life history of the carcinoid tumor of the small intestine. Cancer 14, 901-912 (1961).
5. Wautot V, Vercherat C, Lespinasse J et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum. Mutat. 20(1), 35-47 (2002).
6. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 128(6), 1717-1751 (2005).
7. Moller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid heart disease. N. Engl. J. Med. 348(11), 1005-1015 (2003).
8. Taylor JE, Theveniau MA, Bashirzadeh R, Reisine T, Eden PA. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides 15(7), 1229-1236 (1994).
9. Corness JD, Demchyshyn LL, Seeman P et al. A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS Lett. 321(2-3), 279-284 (1993).
10. Yamada Y, Kagimoto S, Kubota A et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem. Biophys. Res. Commun. 195(2). 844-852 (1993).
11. Xu Y, Song J, Bruno JF, Berelowitz M. Molecular cloning and sequencing of a human somatostatin receptor, hSSTR4. Biochem. Biophys. Res. Commun. 193(2), 648-652 (1993).
12. Rohrer L, Raulf F, Bruns C, Buettner R, Hofstaedter F, Schule R. Cloning and characterization of a fourth human somatostatin receptor. Proc. Natl. Acad. Sci. USA 90(9), 4196-4200 (1993).
13. Demchyshyn LL, Srikant CB, Sunahara RK et al. Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20. Mol. Pharmacol. 43(6), 894-901 (1993).
14. Hoyer D, Bell GI, Berelowitz M et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol. Sci. 16(3), 86-88 (1995).
15. Reubi JC, Kvols LK, Waser B et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 50(18), 5969-5977 (1990).
16. Reubi JC, Krenning E, Lamberts SW, Kvols L. Somatostatin receptors in malignant tissues. J. Steroid Biochem. Mol. Biol. 37(6), 1073-1077 (1990).
17. Reubi JC, Waser B, Khosla S et al. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J. Clin. Endocrinol. Metab. 74(5), 1082-1089 (1992).
18. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 54(13), 3455-3459 (1994).
19. Kubota A, Yamada Y, Kagimoto S et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J. Clin. Invest. 93(3), 1321-1325 (1994).
20. Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J. Steroid Biochem. Mol. Biol. 43(1-3), 27-35 (1992).
21. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab. Invest. 64(4), 567-573 (1991).
22. Bruns C, Weckbecker G, Raulf F et al. Molecular pharmacology of somatostatin-receptor subtypes. Ann. NY Acad. Sci. 733, 138-146 (1994).
23. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N. Engl. J. Med. 334(4), 246-254 (1996).
24. Lamberts SW, Hofland LJ, van Koetsveld PM et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J. Clin. Endocrinol. Metab. 71 (3), 566-574 (1990).
25. Schally AV. Oncological applications of somatostatin analogues. Cancer Res. 48 (24 Pt 1), 6977-6985 (1988).
26. Bauer W, Briner U, Doepfner W et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 31(11), 1133-1140 (1982).
27. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N. Engl. J. Med. 314(18), 1145-1151 (1986).
28. Ardill JE, Erikkson B. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr. Relat. Cancer 10(4), 459-462 (2003).
29. Seregni E, Ferrari L, Bajetta E, Martinetti A, Bombardieri E. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann. Oncol. 12(Suppl. 2). S69-S72 (2001).
30. Krenning EP, Bakker WH, Breeman WA et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1(8632), 242-244 (1989).
31. 111In-DTPA-D-Phe1]-and [1231-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20(8), 716-731 (1993).
32. Frilling A, Malago M, Martin H, Broeisch CE. Use of somatostatin receptor scintigraphy to image extrahepatic metastases of neuroendocrine tumors. Surgery 124(6), 1000-1004 (1998).
33. Krenning EP, Kwekkeboom DJ, Oei HY et al. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann. NY Acad. Sci. 733 416-424 (1994).
34. John M, Meyerhof W, Richter D et al. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 38(1), 33-39 (1996).
35. Nilsson O, Kolby L, Wangberg B et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br. J. Cancer 77(4). 632-637 (1998).
36. Kvols LK, Brown ML, O'Connor MK et al. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology 187(1), 129-133 (1993).
37. Gibril F, Reynolds JC, Lubensky IA et al. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J. Nucl. Med. 41(10), 1646-1656 (2000).
38. Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B. Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur. J. Radiol. 37(1), 8-17 (2001).
39. Dromain C, de Baere T, Lumbroso J et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J. Clin. Oncol. 23(1), 70-78 (2005).
40. Reubi JC, Schar JC, Waser B et al. Affinity profiles for human somatostatin receptor subtypes SST1 -SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27(3), 273-282 (2000).
41. Hofmann M, Maecke H. Borner R et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. 28(12), 1751-1757 (2001).
42. 111 In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol. Imaging Biol. 5(1), 42-48 (2003).
43. de Jong M, Bakker WE, Krenning EP et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phel,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur. J. Nucl. Med. 24(4), 368-371 (1997).
44. 111In-DTPA-octreotide in the same patiens: biodistribution, kinetics, organ and tumor uptake. J. Nucl. Med. 40(5), 762-767 (1999).
45. Maecke HR, Hofmann M, Haberkorn U. (68) Ga-labeled peptides in tumor imaging. J. Nucl. Med. 46(Suppl. 1), S172-S178 (2005).
46. Chamberlain RS, Canes D, Brown KT et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J. Am. Coll. Surg. 190(4), 432-445 (2000).
47. Jaeck D, Oussoultzoglou E, Bachellier P et al. Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery. World J. Surg. 25(6), 689-692 (2001).
48. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery 112(6), 1024-1031 (1992).
49. Touzios JG, Kiely JM, Pitt SC et al. Neuroendocrine hepatic metastases: does aggressive Management improve survival? Ann. Surg. 241(5), 776-783 (2005).
50. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J. Surg. 20(7), 908-914 (1996).
51. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134(6), 1057-1063 (2003).
52. Elias D, Lasser P, Ducreux M et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 133(4), 375-382 (2003).
53. Sarmiento, JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg. Oncol. Clin. N. Am. 12(1), 231-242 (2003).
54. Hellman P, Lundstrom T, Ohrvall et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J. Surg. 26(8), 991-997 (2002).
55. Frilling A, Rogiers X, Malago M, Leedke OM, Kaun M, Broelsch CE. Treatment of liver metastases in patients with neuroendocrine tumors. Langenbecks Arch. Surg. 383(1), 62-70 (1998).
56. Frilling A, Malago M, Weber F et al. Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transpl. 12(7), 1089-1096 (2006).
57. van Vilsteren FG, Baskin-Bey ES, Nagorney DM et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl. 12(3), 448-456 (2006).
58. Welin SV, Janson ET, Sundin A et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur. J. Endocrinol. 151(1), 107-112 (2004).
59. Ruszniewski P, O'Toole D. Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology 80(Suppl. 1), 74-78 (2004).
60. Schnirer II, Yao JC, Ajani JA. Carcinoid - a comprehensive review. Acta Oncol. 42(7), 672-692 (2003).
61. Oberg K, Kvols L, Captin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann. Oncol. 15(6), 966-973 (2004).
62. Oberg K, Eriksson B, Janson ET. The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors. Ann. NY Acad. Sci. 733 471-478 (1994).
63. Hoekstra R, Dumez H, Eskens FA et al. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin. Cancer Res. 11(19 Pt 1), 6908-6915 (2005).
64. Yao JC. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract. Res. Clin. Endocrinol. Metab. 21(1), 163-172 (2007).
65. Ruers TJ, de Jong KP, Ijzermans JN. Radiofrequency for the treatment of liver tumours. Dig. Surg. 22(4), 245-253 (2005).
66. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J. Surg. 26(8), 985-990 (2002).
67. Gupta S, Johnson MM, Murthy R et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104(8), 1590-1602 (2005).
68. O'Toole D, Maire F, Ruszniewski P. Ablative therapies for liver metastases of digestive endocrine tumours. Endocr. Relat. Cancer 10(4), 463-468 (2003).
69. Comaru-Schally AM, Schally AV. A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs (review). Int. J. Oncol. 26(2), 301-309 (2005).
70. Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci. 72(21), 2305-2320 (2003).
71. Krenning EP, de Jong M, Kooij PP et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy. Ann. Oncol. 10(Suppl. 2), S23-S29 (1999).
72. Fjalling M, Andersson P, Forssell-Aronsson E et al. Systemic radionuclide therapy using indium-111-DTPA-D-Phel-octreotide in midgut carcinoid syndrome. J. Nucl. Med. 37(9), 1519-1521 (1996).
73. 111 In-pentetreotide: initial observations and future directions. Cancer J. Sci. Am. 4(2), 94-102 (1998).
74. 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 136(6), 1218-1226 (2004).
75. Valkema R, de JM, Bakker WH et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin. Nucl. Med. 32(2), 110-122 (2002).
76. Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111 In-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J. Nucl. Med. 44(1), 1-6 (2003).
77. Kwekkeboom DJ, Bakker WH, Kooij PP et al. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. Eur. J. Nucl. Med. 27(9), 1312-1317 (2000).
78. Kwekkeboom DJ, Mueller-Brand J, Paganelli G et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J. Nucl. Med. 46(Suppl. 1), S62-S66 (2005).
79. Otte A, Jermann E, Behe M et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur. J. Nucl. Med. 24(7), 792-795 (1997).
80. Otte A, Mueller-Brand J, Deltas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351(9100), 417-418 (1998).
81. Otte A, Herrmann R, Heppeler A et al. Yttrium-90 DOTATOC: first clinical results. Eur. J. Nucl. Med. 26(11), 1439-1447 (1999).
82. 90Y-DOTA-D-Phel-Tyr3-octreotide. Eur. J. Nucl. Med. 28(4), 426-434 (2001).
83. 90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur. J. Nucl. Med. 25(7), 668-674 (1998).
84. 3]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J. Nucl. Med. 42(12), 1841-1846 (2001).
85. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical Phase II study. Ann. Oncol. 12(7), 941-945 (2001).
86. 90Y-DOTATOC) in neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 31(7), 1038-1046 (2004).
87. Mon S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy. Am. J. Kidney Dis. 37(4), 847-851 (2001).
88. Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin. Nucl. Med. 32(2), 141-147 (2002).
89. de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002. Eur. J. Nucl. Med. Mol. Imaging 30(3), 463-469 (2003).
90. Kaltsas GA, Papadogias D, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr. Relat. Cancer 12(4), 683-699 (2005).
91. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 24(4), 389-427 (2003).
92. 90Y-DOTAO,Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin. Nucl. Med. 36(2), 147-156 (2006).
93. Leimer M, Kurtaran A, Smith-Jones P et al. Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J. Nucl. Med. 39(12), 2090-2094 (1998).
94. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin. Nucl. Med. 32(2), 148-155 (2002).
95. Virgolini I, Kurtaran A, Angelberger P, Raderer M, Havlik E, Smith-Jones P. "MAURITIUS": tumour dose in patients with advanced carcinoma. Ital. J. Gastroenterol. Hepatol. 31 (Suppl. 2), S227-S230 (1999).
96. 90Y-DOTATOC. J. Nucl. Med. 46(8), 1310-1316 (2005).
97. 1HIn-DTPAo]octreotide in patients. Eur. J. Nucl. Med. 28(9), 1319-1325 (2001).
98. 0,Tyr3]octreotate. Eur. J. Nucl. Med. Mol. Imaging 30(3), 417-422 (2003).
99. 177Lu-DOTA0, Tyr3]octreotate. J. Clin. Oncol. 22(13), 2724-2729 (2004).
100. 177Lu DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 23(12), 2754-2762 (2005).
101. 90Y-labeled somatostatin analogs. J. Nucl. Med. 46(Suppl. 1), S13-S17 (2005).
102. 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 140(6), 968-976 (2006).
103. 90Y-DOTATOC. J. Nucl. Med. 43(5), 610-616 (2002).
104. Chatal JF, Le Bodic, MF, Kraeber-Bodere F, Rousseau C, Resche I. Nuclear medicine applications for neuroendocrine tumors. World J. Surg. 24(11), 1285-1289 (2000).
105. Rindi G, Kloppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system 2. Virchows Arch. 449(4), 395-401 (2006).